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AbstrAct
Introduction Although inflammation assessed by 
elevated C reactive protein (CRP) concentration is known 
to be associated with risk of cardiovascular disease, 
its association with microvascular and macrovascular 
dysfunction in diabetes and non- diabetes remains 
unclear. We examined the association between CRP and 
diabetes and associated microvascular and macrovascular 
dysfunction in sub- Saharan Africans with and without 
diabetes.
Research design and methods Cross- sectional 
analyses of baseline data from the multicenter RODAM 
study (Research on Obesity and Diabetes among African 
Migrants) including 5248 Ghanaians (583 with diabetes, 
4665 without diabetes) aged 25–70 years were done. 
Logistic regression analyses were used to examine 
the associations between CRP Z- scores and diabetes 
and microvascular (nephropathy) and macrovascular 
(peripheral artery disease (PAD)) dysfunction, with 
adjustments for age, sex, site of residence, smoking, body 
mass index, systolic blood pressure, and low- density 
lipoprotein cholesterol.
Results In the fully adjusted models, higher CRP 
concentration was significantly associated with diabetes 
(adjusted OR 1.13; 95% CI 1.05 to 1.21, p=0.002). In 
participants with diabetes, higher CRP concentration was 
associated with PAD (1.19; 1.03 to 1.41, p=0.046) but 
not nephropathy (1.13; 0.97 to 1.31, p=0.120). Among 
participants without diabetes, higher CRP concentration 
was associated with higher odds of PAD (1.10; 1.01 to 
1.21, p=0.029) and nephropathy (1.12; 1.04 to 1.22, 
p=0.004).
Conclusions In this study, higher CRP concentration was 
associated with higher odds of diabetes in sub- Saharan 
Africans. Also, higher CRP concentration was associated 
with higher odds of nephropathy and PAD in non- diabetes 
and higher odds of PAD in diabetes. CRP may be an 
important marker for assessment of risk of diabetes and 
risk for PAD and nephropathy in sub- Saharan Africans with 
and without diabetes.
InTRoduCTIon
Globally, microvascular and macrovas-
cular diseases are important public health 
problems.1–4 In many regions of the world 
including sub- Saharan Africa, the rates of 
microvascular and macrovascular diseases are 
rising, contributing to the increasing rates 
of disability and death from cardiovascular 
disease (CVD).5 6 Specifically, macrovascular 
significance of this study
What is already known about this subject?
 ► In European and Asian populations, inflammation 
measured by elevated C reactive protein (CRP) is 
known to be associated with diabetes.
 ► Inflammation is a known factor in the development 
of atherosclerosis and subsequent atherosclerotic 
vascular events.
What are the new findings?
 ► In sub- Saharan Africans, higher CRP concentration 
is associated with higher odds of diabetes, even af-
ter adjustments for the conventional cardiovascular 
risk factors.
 ► Higher CRP concentration is significantly associated 
with higher odds of peripheral artery disease (PAD) 
and nephropathy in non- diabetes and higher odds of 
PAD in diabetes.
 ► The conventional cardiometabolic risk factors did 
not explain the associations between CRP and PAD 
and nephropathy in diabetes and non- diabetes.
How might these results change the focus of 
research or clinical practice?
 ► Our findings suggest that CRP could be explored as 
a potential marker to identify sub- Saharan Africans 
at risk of diabetes, PAD and nephropathy.
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Figure 1 Flow chart of study design and inclusion in 
analyses. CRP, C reactive protein.
diseases including peripheral artery disease (PAD), coro-
nary artery disease, and cerebrovascular disease may 
complicate critical limb ischemia, myocardial infarction, 
and stroke, respectively.7 Also, microvascular diseases 
such as retinopathy, nephropathy, and neuropathy may 
result in blindness, end- stage kidney disease, and lower 
limb amputation, respectively.8
C reactive protein (CRP), the most extensively studied 
biomarker of inflammation, is known to be significantly 
associated with CVD including diabetes in European and 
Asian populations; however, data on its role in CVD in 
sub- Saharan African populations are limited.9 10 Consid-
ering the substantial ethnic differences in the association 
between inflammation and diabetes, it may be valuable to 
investigate this association in sub- Saharan African popu-
lations, in the quest to integrate CRP to global risk scores 
for diabetes.11
Existing data on the association between inflamma-
tion and vascular dysfunction have focused on individ-
uals with diabetes.12–14 In diabetes, endothelial injury 
from inflammation mediated by chronic hyperglycemia 
is known to play a key role in the development of vascular 
complications.4 15 However, the effect of glycemic control 
on macrovascular complication risk or progression 
in diabetes remains uncertain.13 16 Also, existing data 
suggest important associations between inflammation 
and CVD in non- diabetes.17 Given the above, it is plau-
sible that inflammation triggered by causes other than 
hyperglycemia may be important in the pathogenesis of 
microvascular and macrovascular dysfunction; however, 
the biological basis for this association has not been clar-
ified.17 We, therefore, assessed the associations between 
CRP and diabetes in Ghanaians. In addition, we assessed 
associations between CRP and microvascular (nephrop-
athy) and macrovascular dysfunction (PAD) in Ghana-
ians with and without diabetes.
MaTeRIals and MeTHods
study design
The rationale, conceptual framework, design and meth-
odology of the RODAM study (Research on Obesity and 
Diabetes among African Migrants) have been described in 
detail elsewhere.18 In brief, the study was conducted from 
2012 to 2015 and comprised Ghanaians aged 25–70 years 
living in rural and urban Ghana as well as in three Euro-
pean cities, namely Amsterdam, Berlin and London. 
Data collection for the study was standardized across all 
sites. Informed written consent was also obtained from 
each participant prior to enrollment in the study. For the 
current analyses, only participants with complete data on 
CRP, microvascular disease (nephropathy) and macrovas-
cular disease (PAD) were included. This comprised data 
from 583 participants with diabetes and 4665 participants 
without diabetes aged 25–70 years (figure 1).
assessments
Questionnaires
A structured questionnaire18 was used to record the 
demographic, socioeconomic, and health- related behav-
iors of the study participants. Smoking was assessed as 
a positive reply to the question ‘Do you smoke at all?’ 
Alcohol intake in grams per day was estimated using stan-
dard portion sizes combined with frequencies of intake 
based on a standardized Food Propensity Question-
naire.19 Physical activity was derived for each participant 
using the International Physical Activity Questionnaire, 
and participants were classified into three categories of 
total physical activity, namely low, moderate and high 
level.20
Physical examination
According to standard operation procedures, weight was 
measured in light clothing and without shoes with SECA 
877 scales to the nearest 0.1 kg. Height was measured 
without shoes with SECA 217 stadiometer to the nearest 
0.1 cm. Body mass index (BMI) was calculated as weight 
(kg) divided by height squared (m2). Blood pressure 
(BP) was measured three times using the Microlife 
WatchBP home device, with appropriately sized cuffs 
after at least 5 min rest while seated. The mean of the last 
two BP measurements was used for the analyses. Hyper-
tension was defined as systolic BP ≥140 mm Hg and/or 
diastolic BP ≥90 mm Hg, and/or being on antihyperten-
sive medication treatment. All the anthropometrics were 
measured twice by the same assessor and the average of 
the two measurements was used for analyses.
Ankle- brachial pressure index (ABI) measurements 
were performed in supine position using a validated 
oscillometric device (WatchBP Office ABI, Microlife, 
Widnau) with appropriately sized cuffs after at least 
10 min of supine rest.21 Systolic BP was measured twice 
in the right and left brachial artery and twice in the right 
and left posterior tibial arteries. ABI was calculated by 
taking the highest arm systolic BP as the denominator 
and the lowest ankle BP as the numerator.22 The lowest 
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of the left and right ABI measurements was used for anal-
yses. ABI obtained by the oscillometric method using 
the Microlife WatchBP Office ABI has been shown to 
correlate well with ABI acquired by Doppler ultrasound 
with 95% agreement between the two methods in diag-
nosing PAD.23
Biochemical analyses
According to standard operation procedures, fasting 
venous blood samples were processed and aliquoted 
into Sarstedt tubes after collection, registered and 
then temporarily stored at the research site at −20°C. 
Aliquoted blood samples and first early morning urine 
sample were transported to the local research centers, 
where they were checked, registered and stored at 
−80°C before being shipped to the central laboratory at 
Charité-University Medicine Berlin (Berlin, Germany) 
for determination of biochemical variables. Shipping of 
the samples from European sites was carried out using 
Styrofoam boxes filled with dry ice and from Ghana 
in dry shippers filled with liquid nitrogen. Extensive 
quality checks were done during the biochemical anal-
ysis, including blinded serial measurements. Fasting 
glucose, total cholesterol, low- density lipoprotein (LDL) 
cholesterol, high- density lipoprotein cholesterol, and 
triglycerides levels were determined using the ABX 
Pentra 400 Chemistry Analyzer (HORIBA ABX, Mont-
pellier, France). Fasting plasma glucose concentration 
was measured using an enzymatic method (hexokinase). 
The concentration of total cholesterol was assessed 
using colorimetric test kits. Glycosylated hemoglobin 
(HbA1c) was measured by high- performance liquid chro-
matography (Tosoh G8 HPLC Analyzer). The concen-
tration of urinary albumin (in µmol/L) was measured 
by an immunochemical turbidimetric method (Roche 
Diagnostics) and urinary creatinine concentration 
(in µmol/L) was measured by a kinetic spectrophoto-
metric method (Roche Diagnostics). Urinary albumin 
to creatinine ratio (ACR; expressed in mg/mmol) was 
calculated by taking the ratio between urinary albumin 
and urinary creatinine. Serum creatinine concentration 
was determined by a kinetic colorimetric spectrophoto-
metric isotope dilution mass spectrometry calibration 
method (Roche Diagnostics). The estimated glomer-
ular filtration rate (eGFR) was calculated using the 
2009 CKD- EPI (Chronic Kidney Disease Epidemiology 
Collaboration) creatinine equation. High- sensitive CRP 
(hs- CRP) levels were measured in heparin plasma by a 
particle enhanced immunoturbidimetric assay. Human 
CRP agglutinates with latex particles were coated with 
monoclonal anti- CRP antibodies. The aggregates were 
determined turbidimetrically using Pentra 400 Chem-
istry Analyzer (HORIBA ABX). Z- scores were computed 
for each participant based on the participant’s CRP 
concentration (x), mean CRP concentration (µ) and SD 
(σ). We computed the Z- scores as: Z- score=(x−µ)/σ.
Definition of diabetes and microvascular and microvascular 
dysfunction
Diabetes was defined according to the WHO diagnostic 
criteria (self- reported diabetes, documented use of 
glucose- lowering medication(s), fasting plasma glucose 
≥7.0 mmol/L) or HbA1c ≥6.5% or ≥48 mmol/mol.
24 PAD 
was defined as ABI ≤0.90.22 ABI >1.3 was not considered 
normal as it could be suggestive of non- compressible 
vessels.22 Albuminuria and eGFR were classified 
according to the 2012 Kidney Disease: Improving Global 
Outcomes (KDIGO) guidelines.25 eGFR was classified as 
follows: G1, 90 mL/min/1.73 m2 (normal kidney func-
tion); G2, 60–89 mL/min/1.73 m2 (mildly decreased); 
G3a, 45–59 mL/min/1.73 m2 (mildly to moderately 
decreased); G3b, 30–44 mL/min/1.73 m2 (moderately 
to severely decreased); G4, 15–29 mL/min/1.73 m2 
(severely decreased); and G5, <15 mL/min/1.73 m2 
(kidney failure). Low eGFR was defined as eGFR <60 mL/
min/1.73 m2 (category ≥G3).26 Albuminuria classifica-
tions were derived from ACR and were as follows: A1, 
<3 mg/mmol (normal to mildly increased); A2, 3–30 mg/
mmol (moderately increased); and A3, >30 mg/mmol 
(severely increased). Because of the small number of 
participants in the severely increased albuminuria cate-
gory (A3), we combined the moderately increased (A2) 
and severely increased (A3) categories.25 26 Nephrop-
athy was defined as albuminuria and/or eGFR <60 mL/
min/1.73 m2 based on the KDIGO guidelines.25 27
statistical analysis
Data were analyzed using the IBM SPSS V.23 for 
Windows. Data with normal distributions were presented 
as mean±SD, whereas those not normally distributed 
presented as median (IQR). Categorical data were 
presented as frequencies (percentages). No significant 
interaction between site of residence and CRP was found; 
therefore, we did not stratify the analyses by site of resi-
dence. However, we used site as a covariate in our logistic 
regression models. Logistic regression analyses were used 
to examine the associations between CRP concentrations 
and diabetes, PAD and nephropathy with adjustments for 
covariates. ORs and their corresponding 95% CIs were 
estimated. The minimal sufficient adjustment sets for 
estimating the direct effect of CRP on PAD and nephrop-
athy were determined by a directed acyclic graph (DAG) 
(online supplementary figure 1; DAG available at  dagitty. 
net/ mGETVa3). DAG was chosen because the tradi-
tional methods of adjusting for potential confounders 
may introduce conditional associations and bias rather 
than minimize it.28 Based on the DAG, the minimal suffi-
cient adjustment sets for estimating the total effect of 
CRP on vascular dysfunction were age, smoking, obesity, 
hypertension, diabetes and dyslipidemia. Three models 
were used to examine the data. Model 1 was unadjusted, 
model 2 was adjusted for age and sex, and in model 3 we 
additionally adjusted for site of residence, smoking, BMI, 
systolic BP, diabetes and LDL- cholesterol. In the diabetes 
and non- diabetes subgroup analyses, we adjusted for 
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age, sex, site of residence, smoking, BMI, systolic BP, and 
LDL- cholesterol in model 3.
ResulTs
Baseline characteristics
Table 1 shows the baseline characteristics of the study 
participants. Compared with participants without 
diabetes, participants with diabetes were less frequently 
female, less physically active, much older, consumed 
more alcohol and had a lower proportion of people who 
have never smoked. Also, the mean BMI, waist circum-
ference, hip circumference, waist to hip ratio, systolic 
BP, diastolic BP, total cholesterol and LDL- cholesterol 
were higher in participants with diabetes than their 
peers without diabetes. The median CRP concentration 
and proportion of participants with CRP >3 mg/L were 
higher in participants with diabetes than those without 
diabetes. Participants with diabetes had higher rates of 
PAD and nephropathy than their peers without diabetes.
association between CRP and diabetes
Higher CRP Z- score concentration was associated 
with higher odds of diabetes in the unadjusted model 
(figure 2). The association persisted in a fully adjusted 
model (adjusted OR (AOR) 1.13; 95% CI 1.05 to 1.21, 
p=0.002). In a sensitivity analysis, we excluded partic-
ipants with CRP concentrations >10 mg/L; the SD of 
the mean CRP was 8.20 mg/L for the whole group and 
2.07 mg/L for the subgroup with CRP concentrations 
≤10 mg/L. In participants with CRP concentrations 
≤10 mg/L (n=4962), higher CRP Z- score concentration 
was significantly associated with higher odds of diabetes 
in both the unadjusted (OR 1.31; 95% CI 1.22 to 1.42, 
p<0.001) and fully adjusted (AOR 1.24; 95% CI 1.14 to 
1.36, p<0.001) models.
association between CRP and microvascular and 
macrovascular dysfunction
In participants without diabetes, higher CRP Z- score 
concentration was associated with higher odds of PAD 
and nephropathy (table 2). The differences persisted in 
the fully adjusted model: PAD (AOR 1.10; 95% CI 1.01 
to 1.21, p=0.029) and nephropathy (AOR 1.12; 95% CI 
1.04 to 1.22, p=0.004). Among participants with diabetes, 
higher CRP Z- score concentration was also associated 
with PAD and nephropathy. The associations remained 
statistically significant in the fully adjusted models for 
PAD (AOR 1.19; 95% CI 1.03 to 1.41, p=0.046), but not for 
nephropathy (AOR 1.13; 95% CI 0.97 to 1.31, p=0.120).
In the analysis of the association between higher CRP 
Z- score concentration and the individual components of 
nephropathy, higher CRP Z- score concentration was asso-
ciated with higher odds of albuminuria and low eGFR in 
the non- diabetes group. The differences persisted in the 
fully adjusted model for albuminuria (AOR 1.15; 95% CI 
1.05 to 1.24, p=0.001), but not for low eGFR (AOR 
1.07; 95% CI 0.94 to 1.21, p=0.316). Among participants 
with diabetes, higher CRP Z- score concentration was 
associated with higher odds of albuminuria, but not with 
low eGFR in the unadjusted model. In the fully adjusted 
model the association between higher CRP Z- score 
concentration and albuminuria was no longer statistically 
significant (AOR 1.16; 95% CI 0.99 to 1.36, p=0.066).
The sensitivity analysis showing the associations 
between CRP Z- score concentration and PAD and 
nephropathy in participants with CRP concentrations 
≤10 mg/L is shown in table 3. In the non- diabetes group 
with CRP ≤10 mg/L, higher CRP Z- score concentrations 
were significantly associated with higher odds of PAD and 
nephropathy. The associations were no longer statistically 
significant in the fully adjusted model: PAD (AOR 1.06; 
95% CI 0.93 to 1.21, p=0.372) and nephropathy (AOR 
1.32; 95% CI 0.87 to 1.99, p=0.194). In participants with 
diabetes with CRP concentrations ≤10 mg/L, higher CRP 
Z- score concentration was not significantly associated 
with PAD or nephropathy: PAD (AOR 1.05; 95% CI 0.75 
to 1.47, p=0.785) and nephropathy (AOR 1.69; 95% CI 
0.77 to 3.71, p=0.189).
dIsCussIon
Key findings
Using a sample of Ghanaians, we showed that among sub- 
Saharan Africans higher CRP concentration is associated 
with higher odds of diabetes, even after adjustments for 
the conventional cardiovascular risk factors. Additionally, 
higher CRP concentration is significantly associated with 
higher odds of nephropathy and PAD in non- diabetes 
and higher odds of PAD in diabetes. The conventional 
cardiometabolic risk factors did not explain the associ-
ations between CRP and PAD and/or nephropathy in 
diabetes and non- diabetes.
discussion of key findings
This is the first study assessing the relationship between 
CRP and diabetes among a sub- Saharan African popu-
lation. The results of our study in Ghanaians suggest 
an association between higher CRP and higher odds of 
diabetes in sub- Saharan Africans. A systematic review and 
meta- analysis by Wang et al10 had previously shown that 
elevated levels of inflammatory markers were significantly 
associated with increased risk of diabetes. The data on 
which this conclusion was based excluded sub- Saharan 
Africa origin populations. Considering the ethnic differ-
ences in the association between inflammation and 
diabetes, data on this association in sub- Saharan Africans 
are important in the quest to integrate CRP to global risk 
scores for diabetes.29 Our finding of a positive association 
between CRP and diabetes has confirmed earlier find-
ings and expanded the evidence to sub- Saharan African 
populations. Considering the persistence of a statistically 
significant association between higher CRP concentra-
tion and higher odds of diabetes after excluding individ-
uals with CRP concentrations >10 mg/L, our results could 
reflect the role of subclinical inflammation, instead of 
acute infection. Our cross- sectional analyses also suggest 
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Female 3263 (62.2%) 2938 (63.0%) 325 (55.7%) 0.001
Age, years 46.16 (±11.48) 45.25 (±11.72) 52.65 (±9.73) <0.001
Higher or tertiary education 550 (10.7%) 486 (10.6%) 64 (11.2%) 0.578
Physical activity <0.001
  Low level 1423 (30.6%) 1225 (29.6%) 198 (38.7%)
  Moderate level 917 (19.7%) 812 (19.6%) 105 (20.5%)
  High level 2306 (49.6%) 2099 (50.7%) 207 (40.5%)
Body mass index, kg/m2 26.79 (±5.36) 26.76 (±5.37) 29.18 (±5.84) <0.001
Waist circumference, cm 90.18 (±12.64) 89.23 (±12.26) 97.80 (±13.08) <0.001
Hip circumference, cm 100.33 (±11.65) 99.92 (±11.57) 103.65 (±11.76) <0.001
Waist to hip ratio 0.90 (±0.07) 0.89 (±0.07) 0.94 (±0.07) <0.001
Alcohol consumption, g/day 0.14 (1.99) 0.14 (1.87) 0.58 (3.14) 0.067
Smoking status <0.001
  Current smokers 151 (2.9%) 135 (2.9%) 16 (2.8%)
  Previous smokers 375 (7.2%) 303 (6.6%) 72 (12.4%)
  Never smoked 4667 (89.9%) 4176 (90.5%) 491 (84.8%)
Systolic BP, mm Hg 129.38 (±19.55) 129.12 (±19.35) 138.11 (±19.47) <0.001
Diastolic BP, mm Hg 81.08 (±11.97) 80.86 (±11.94) 84.80 (±11.31) <0.001
Hypertension 2391 (45.6%) 1952 (41.8%) 439 (75.3%) <0.001
HbA1c, mmol/mol 37.93 (±12.90) 35.61 (±6.06) 59.30 (±22.97) <0.001
Glucose, mmol/L 5.40 (±1.96) 5.01 (±0.58) 8.19 (±4.25) <0.001
Total cholesterol, mmol/L 5.02 (±1.14) 4.94 (±1.10) 5.19 (±1.33) <0.001
Triglycerides, mmol/L 1.03 (±0.56) 0.98 (±0.53) 1.25 (±0.73) <0.001
LDL- cholesterol, mmol/L 3.22 (±0.99) 3.16 (±0.95) 3.34 (±1.18) <0.001
HDL- cholesterol, mmol/L 1.33 (±0.36) 1.34 (±0.36) 1.29 (±0.34) 0.003
CRP concentration, mg/L 0.70 (2.30) 0.70 (2.10) 1.50 (4.40) <0.001
CRP categories <0.001
  CRP ≤3 mg/L 4124 (78.6%) 3734 (80.0%) 390 (66.9%)
  CRP >3 mg/L 1124 (21.4%) 931 (20.0%) 193 (33.1%)
ACR, mg/mmol 0.57 (0.73) 0.55 (0.67) 0.80 (1.37) <0.001
ACR ≥3 mg/mmol 471 (9.0%) 373 (8.0%) 98 (16.8%) <0.001
eGFR, mL/min/1.73 m2 95.26 (±20.18) 90.61 (±19.68) 95.84 (±20.17) <0.001
eGFR <60 mL/min/1.73 m2 165 (3.1%) 130 (2.8%) 35 (6.0%) <0.001
Nephropathy 593 (11.3%) 470 (10.1%) 123 (21.1%) <0.001
ABI (left side) 1.16 (±0.13) 1.16 (±0.13) 1.18 (±0.13) 0.003
ABI (right side) 1.15 (±0.13) 1.15 (±0.13) 1.17 (±0.13) 0.036
ABI categories 0.022
  ≤0.90 312 (5.9%) 273 (5.9%) 39 (6.7%)
  0.91–1.30 4711 (89.8%) 4204 (90.1%) 507 (87.0%)
  >1.30 225 (4.3%) 188 (4.0%) 37 (6.3%)
Values for categorical variables are given as number (percentage), and for continuous variables as mean (±SD) or median (IQR).
ABI, ankle- brachial pressure index; ACR, albumin to creatinine ratio; BP, blood pressure; CRP, C reactive protein; eGFR, estimated glomerular 
filtration rate; HbA1c, glycosylated hemoglobin; HDL, high- density lipoprotein; LDL, low- density lipoprotein.
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Figure 2 OR of diabetes per SD increase in the CRP 
concentration. Model 1 was unadjusted; model 2 adjusted 
for age and sex; model 3 adjusted additionally for site of 
residence, smoking, BMI, systolic blood pressure, and LDL- 
cholesterol. SD of mean CRP=8.20 mg/L for the whole group 
(n=5248); SD of mean CRP=2.07 mg/L for the subgroup of 
participants with CRP concentrations ≤10 mg/L (n=4962). 
BMI, body mass index; CRP, C reactive protein; LDL, low- 
density lipoprotein.
Table 2 Association between CRP Z- scores and microvascular/macrovascular dysfunction
Whole cohort (n=5248) Non- diabetes group (n=4665) Diabetes group (n=583)
OR (95% CI), p value OR (95% CI), p value OR (95% CI), p value
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3












































































































Whole group analyses: model 1 was unadjusted; model 2 adjusted for age and sex; model 3 adjusted additionally for site of residence, 
smoking, BMI, systolic blood pressure, diabetes and LDL- cholesterol.
Subgroup (diabetes and non- diabetes) analyses: model 1 was unadjusted; model 2 adjusted for age and sex; model 3 adjusted additionally 
for site of residence, smoking, BMI, systolic blood pressure, and LDL- cholesterol.
BMI, body mass index; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; LDL, low- density lipoprotein; PAD, peripheral 
artery disease.
that a reciprocal association between inflammation and 
diabetes could exist as diabetes may lead to impaired 
immunity and increase the risk of chronic infections 
and/or infestations with subsequent rise in the levels of 
inflammatory markers.30
Although inflammation measured by CRP is a known 
risk factor for CVD, its associations with microvascular 
and macrovascular dysfunction in diabetes and in non- 
diabetes are unclear. In diabetes, most studies inves-
tigating this relationship have reported significant 
positive association between inflammation and vascular 
complications.12 31 32 Our results show that in sub- 
Saharan Africans with diabetes, higher CRP concentra-
tion is positively associated with PAD. The associations 
persisted after adjustments for the conventional cardio-
vascular risk factors. These findings resemble results 
previously reported in other populations.31 32 In this 
current study, we did not find a statistically significant 
association between CRP and nephropathy in partici-
pants with diabetes. Existing data in other ethnic groups 
suggest that higher CRP concentration is associated with 
nephropathy in diabetes.33 The direction of the associa-
tion between CRP and nephropathy in previous studies 
is the same in the current study; therefore, it is possible 
that limited power restricted us from finding a significant 
association between CRP and nephropathy in diabetes.
There are limited data on the association between CRP 
and microvascular/macrovascular dysfunction in individ-
uals without diabetes. Our study shows that in sub- Saharan 
Africans without diabetes, higher CRP concentration is 
significantly associated with PAD and nephropathy. This 
finding highlights the role of inflammation in the patho-
genesis of microvascular/macrovascular dysfunction, 
independent of hyperglycemia.17 34 This has important 
implications in low- to- middle- income regions like sub- 
Saharan Africa, where in addition to the growing burden 
of obesity and diabetes there is a high burden of proin-
flammatory conditions, including chronic or recurrent 
infections and infestations.6 11 35 36 Chronic intravascular 
infections and infestations may trigger the inflamma-
tory pathways, predisposing the macrovasculature and 
microvasculature to accelerated atherosclerosis.17 37 Also, 
chronic extravascular infections can enhance extravas-
cular production of inflammatory cytokines that may 
accelerate the process of atherosclerosis.17 The conven-
tional cardiometabolic risk factors did not significantly 
attenuate the association between CRP and PAD or 
nephropathy in non- diabetes. This further highlights 
7BMJ Open Diab Res Care 2020;8:e001235. doi:10.1136/bmjdrc-2020-001235
Cardiovascular and Metabolic Risk
Table 3 Association between CRP Z- scores and microvascular/macrovascular dysfunction in participants with CRP 
concentrations ≤10 mg/L
Whole cohort (n=4962) Non- diabetes group (n=4430) Diabetes group (n=532)
OR (95% CI), p value OR (95% CI), p value OR (95% CI), p value
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3












































































































Whole group analyses: model 1 was unadjusted; model 2 adjusted for age and sex; model 3 adjusted additionally for site of residence, 
smoking, BMI, systolic blood pressure, diabetes and LDL- cholesterol.
Subgroup (diabetes and non- diabetes) analyses: model 1 was unadjusted; model 2 adjusted for age and sex; model 3 adjusted additionally 
for site of residence, smoking, BMI, systolic blood pressure, and LDL- cholesterol.
BMI, body mass index; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; LDL, low- density lipoprotein; PAD, peripheral 
artery disease.
the fact that the inflammatory pathways driving micro-
vascular and macrovascular dysfunction may not be 
fully dependent on the conventional cardiovascular risk 
factors. Indeed, we have previously reported that the 
higher rates of microvascular and macrovascular dysfunc-
tion in sub- Saharan Africans living in Africa compared 
with their peers in Europe are not fully explained by 
glycemic control or the conventional cardiovascular risk 
factors.38 39
Overall, our results support the idea that some process 
related to persistent inflammation is associated with 
microvascular and macrovascular dysfunction, although 
the clinical utility of this remains unclear, especially in 
the setting of low- income to middle- income countries 
where the likelihood of low- grade inflammation from 
non- hyperglycemic causes including chronic infec-
tions and infestations is high.36 Based on the CANTOS 
trial (Canakinumab Anti- Inflammatory Thrombosis 
Outcomes Study), anti- inflammatory therapy targeting 
the interleukin-1β pathway significantly reduced macro-
vascular events.40 Although not previously investigated, 
the finding from the CANTOS trial may suggest that 
interventions aimed at controlling low- grade inflamma-
tion may be valuable in curbing the rates of microvascular 
and macrovascular dysfunction. This may include rela-
tively less expensive interventions like control of chronic 
infections and infestations. Another clinical significance 
of our results is the potential of using CRP as a marker for 
assessing or monitoring the risk of developing vascular 
dysfunction in individuals with and without diabetes. 
This could aid early detection of vascular dysfunction, 
improve quality of life and reduce healthcare- related 
costs through preventive interventions.
limitations
Our study has some limitations. First, we used hs- CRP as 
the marker of inflammation. hs- CRP does not necessarily 
reflect the degree of inflammation of individual tissues. 
Additionally, CRP is only one marker of inflammation 
and other markers such as fibrinogen and D- dimer were 
not measured in our study. Second, we did not have data 
on existing acute infections or infestations; however, we 
excluded participants with CRP concentrations >10 mg/L 
in a sensitivity analysis. Third, the sample size among 
individuals with diabetes was relatively small, limiting the 
power to detect associations between CRP and vascular 
complications in diabetes. Fourth, the microvascular 
dysfunction of retinopathy and neuropathy, as well as 
the macrovascular dysfunction of coronary artery disease 
and cerebrovascular disease, were not assessed. Fifth, we 
did not perform the 2- hour postload plasma glucose in 
identifying participants with diabetes; this could have 
underdiagnosed participants with diabetes.24 Finally, the 
duration of diabetes was not included as a covariate in 
the multivariable analysis for participants with diabetes 
because many study participants did not provide this 
information.
ConClusIon
In our study, higher CRP concentration was associated 
with higher odds of diabetes. Higher CRP concentra-
tion was also associated with higher odds of PAD and 
nephropathy in non- diabetes and higher odds of PAD in 
diabetes. Our data from this first study on CRP in rela-
tion to diabetes and microvascular and macrovascular 
dysfunction in a sub- Saharan African population suggest 
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that CRP could be explored as a potential marker to 
identify sub- Saharan African patients with diabetes at 
risk for macrovascular complications. Additionally, our 
finding of an association with higher odds of diabetes 
and both microvascular and macrovascular dysfunction 
in non- diabetes individuals implies that CRP could play 
a role in the assessment of risk before diabetes diag-
nosis, for example, in pre- diabetes individuals. In both 
individuals with and without diabetes, interventions 
aimed at controlling inflammation may help reduce the 
risk of diabetes and microvascular and macrovascular 
dysfunction.
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